Join Growin Stock Community!

慧智6615.TW Overview

TW StockBiotech. & Medical
(No presentation for 6615)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

慧智（6615）Overall Performance

慧智（6615）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

慧智（6615） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

慧智（6615）Key Information

慧智（6615）Profile

Sofiva Genomics Co.,Ltd. provides genetic testing services in Taiwan and internationally. The company offers prenatal services, including thalassemia carrier screening; tests for microdeletion syndromes and single-gene abnormalities; detection of common chromosome abnormalities, selected microdeletions syndromes, and selected skeletal dysplasia genetic mutations; multiple genetic diseases detection; folate metabolism genetic screening; spinal muscular atrophy carrier screening; fragile X syndrome carrier screening; congenital infection screening; risk assessment for early/late-onset preeclampsia; maternal serum screening for down syndrome; and karyotyping. It also provides cancer services, such as cancer scans; real-time monitoring of tumor dynamics; hereditary cancer related genetic tests; and hereditary women's cancer tests for breast, colon, ovarian, and endometrial cancer, as well as human papillomavirus screening. In addition, the company offers rare diseases genetic testing services; and preimplantation genetic diagnosis and NGS-based preimplantation genetic screening services. Further, it provides new-born genetic testing services comprising baby scans; hereditary sensorineural hearing loss screening; congenital central hypoventilation syndrome screening; congenital cytomegalovirus infection screening test; and atopic dermatitis genetic screening. Additionally, the company offers biochemical and chromosome testing, as well as advisory and support services. It serves expectant parents, patients with genetic disorders, and their families. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.

慧智（6615）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
12.47
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
26.32%
Net Margin
-2.59%
Revenue Growth (YoY)
-15.32%
Profit Growth (YoY)
-24.73%
3-Year Revenue Growth
-8.01%
3-Year Profit Growth
-7.24%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
12.47
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
26.32%
Net Margin
-2.59%
Revenue Growth (YoY)
-15.32%
Profit Growth (YoY)
-24.73%
3-Year Revenue Growth
-8.01%
3-Year Profit Growth
-7.24%
default symbol

6615

慧智

35.90D

0.70%

(0.01)

  • When is 6615's latest earnings report released?

    The most recent financial report for 慧智 (6615) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6615's short-term business performance and financial health. For the latest updates on 6615's earnings releases, visit this page regularly.

  • What is the operating profit of 6615?

    According to the latest financial report, 慧智 (6615) reported an Operating Profit of -4.97M with an Operating Margin of -5.32% this period, representing a growth of 28.82% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6615's revenue growth?

    In the latest financial report, 慧智 (6615) announced revenue of 93.41M, with a Year-Over-Year growth rate of -12.08%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6615 have?

    At the end of the period, 慧智 (6615) held Total Cash and Cash Equivalents of 76.54M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6615 go with three margins increasing?

    In the latest report, 慧智 (6615) did not achieve the “three margins increasing” benchmark, with a gross margin of 26.78%%, operating margin of -5.32%%, and net margin of -1.27%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6615's profit trajectory and future growth potential.

  • Is 6615's EPS continuing to grow?

    According to the past four quarterly reports, 慧智 (6615)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6615?

    慧智 (6615)'s Free Cash Flow (FCF) for the period is 3.94M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 56.49% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.